Baxter Sells Sunshine Its Ultrafiltration Treatment Products
Tuesday, August 9, 2016
Sunshine Heart ($SSH) has acquired Baxter International’s ($BAX) line of Aquadex products. Per the agreement, Baxter will bring in $4 million in cash and 1 million shares of Sunshine’s common stock.
The Aquadex line is used for temporary and extended ultrafiltration treatment for those experiencing fluid overload who also don’t respond to diuretic therapy. Temporary treatment can last up to 8 hours, while extended therapy is longer than 8 hours and the patient requires hospitalization.
John Erb, chairman and CEO of Sunshine, noted in the announcement that the investment will help strengthen Sunshine’s presence in the heart failure market.